Selank — Research Overview

Selank is a synthetic heptapeptide analog of the endogenous immunomodulatory tetrapeptide tuftsin, with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Developed in Russia at the Institute of Molecular Genetics, it was designed to enhance the stability and bioavailability of tuftsin while retaining and expanding its biological activity profile. Unlike conventional anxiolytic compounds that act through GABAergic receptor modulation and carry sedative or dependency-associated properties, Selank has been studied for its influence on multiple neurotransmitter systems including serotonin, dopamine, and norepinephrine pathways, as well as its observed effects on BDNF expression and enkephalin metabolism. This multi-system profile has made it a compound of interest in neurological, immunological, and behavioral research. Available from 4-LD in lyophilized form, Selank is produced under quality-controlled conditions exclusively for qualified researchers and laboratory professionals conducting in-vitro and controlled research applications.

Areas of Active Research

Selank has been studied across several active research areas. In anxiety and stress response research, rodent behavioral models including elevated plus maze, open field, and forced swim tests have examined its anxiolytic-like properties, with findings suggesting it modulates the HPA axis stress response and influences corticotropin-releasing hormone signaling without producing the sedative effects or withdrawal phenomena associated with classical anxiolytic compounds. In cognitive and neurotrophin research, studies have examined its effects on BDNF upregulation and enkephalin degradation inhibition, with animal model findings suggesting associations between Selank administration and improvements in learning and memory task performance, attention, and information processing capacity. In neurotransmitter system research, studies have investigated its influence on serotonergic, dopaminergic, and noradrenergic signaling in brain tissue, with findings documenting effects on monoamine turnover rates that may underlie its observed behavioral profile in preclinical models. In immunomodulatory research, studies derived from its tuftsin structural origin have examined its effects on immune cell function including macrophage activity, cytokine production profiles, and interferon expression, with findings suggesting it may influence the balance between innate and adaptive immune responses. In neurological protection research, preclinical models have explored its potential effects on neuronal resilience under conditions of oxidative stress and ischemic injury. All findings referenced are from preclinical and in-vitro studies. This product is intended solely for laboratory research by qualified professionals and is not for human or animal consumption. 4-LD makes no therapeutic claims regarding this compound.